FBL20 Activators
FBL20 activators can be divided into two groups. The first group includes compounds that increase the level of cAMP (Forskolin, Rolipram, 8-Bromo-cAMP, IBMX, Dibutyryl-cAMP, Epinephrine, Isoproterenol, NECA, BAY 60-6583, Salbutamol). cAMP is a secondary messenger that is regulated by adenylyl cyclase, the enzyme that synthesizes cAMP, and phosphodiesterases (PDEs) that degrade it. Some of these compounds directly activate adenylyl cyclase (Forskolin, Epinephrine, Isoproterenol, NECA, BAY 60-6583, Salbutamol), while others inhibit PDEs (Rolipram, IBMX), leading to increased cAMP levels. FBL20 is a part of the STRIPAK complex, which interacts with cAMP-dependent protein kinases (PKA). Hence, increased cAMP levels enhance FBL20 activity by increasing its interaction with PKA.
The second group of FBL20 activators includes compounds that increase the level of another secondary messenger, cGMP (BAY 73-6691, Sildenafil). cGMP is a crucial mediator of various biological responses, and its level is regulated by guanylyl cyclase, the enzyme that synthesizes cGMP, and phosphodiesterases (PDEs) that degrade it. In this group, BAY 73-6691 inhibits PDE9, while Sildenafil inhibits PDE5, both leading to increased cGMP levels. Similar to cAMP-dependent kinases, FBL20, as part of the STRIPAK complex, also interacts with cGMP-dependent kinases. Therefore, increased cGMP levels enhance its activity through this interaction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase increasing cAMP levels. FBL20 is part of the STRIPAK complex, which interacts with cAMP-dependent protein kinases, thus enhancing FBL20 activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective PDE4 inhibitor that increases cAMP levels. FBL20, being part of the STRIPAK complex, interacts with cAMP-dependent protein kinases, hence enhancing its activity. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog. Increased cAMP level enhances FBL20 activity through its interaction with cAMP-dependent protein kinases. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX inhibits phosphodiesterases leading to increased cAMP levels. FBL20 interacts with cAMP-dependent protein kinases, thereby increasing its activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cell-permeable cAMP analog. The interaction of FBL20 with cAMP-dependent protein kinases is enhanced by increased cAMP levels. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine activates adenylyl cyclase to increase cAMP levels. This enhances FBL20 activity through its interaction with cAMP-dependent protein kinases. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol activates adenylyl cyclase, increasing cAMP levels. This enhances FBL20 activity due to its interaction with cAMP-dependent kinases. | ||||||
BAY 60-6583 | 910487-58-0 | sc-503262 | 10 mg | $210.00 | ||
BAY 60-6583 is an adenosine A2B receptor agonist that increases cAMP levels, enhancing FBL20 activity through its interaction with cAMP-dependent kinases. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol is a beta2-adrenergic receptor agonist. It increases cAMP levels, enhancing FBL20 activity through its interaction with cAMP-dependent kinases. | ||||||
BAY 73-6691 | 794568-92-6 | sc-252407 | 5 mg | $247.00 | 2 | |
BAY 73-6691 is a selective inhibitor of PDE9, leading to increased cGMP levels. FBL20 interacts with cGMP-dependent protein kinases, hence increased cGMP levels enhance its activity. | ||||||